To investigate whether the immunologic features in the de novo IL2 response classifier were shared with the established prognostically poor ccB subtype, the de novo IL2 response classifier and an established ccA/ccB classifier (27) were applied to a randomly sampled subset of patients with RCC (n = 253) from TCGA (patients who are treated with various standards of care including IL2; Fig. 3A). This evidence concerns the gene IL2 and renal cell carcinoma.